Corporate News

【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Medicilon’s Formulation CDMO Platform Advances Taiji Group’s Next-Generation RNA Polymerase Inhibitor DSC158A Tablets to Clinical Stage
TPD CN-US Dual Filing Milestone: Medicilon’s One-Stop Platform Helps Gluetacs Secure Dual Approval for GT818, a First-in-Class RSK Degrader
World’s First Long-Acting Anti-RSV Monoclonal Antibody Xinduotuo Wins NMPA Approval — Medicilon Empower Trinomab’s Source Innovation
Novel Analgesic Breakthrough: Xinhua Pharmaceutical’s Class 1 Drug LXH-2103 Secures Clinical Approval with Medicilon’s Preclinical Support
Medicilon Empowers IxCell’s IxCell PB-ZRAK Injection to Secure Clinical Trial Approval for Advanced Hepatocellular Carcinoma

Events

EFMC-ISMC 2026
4th SMC and AimedBio ADC Conference
ACS Fall 2026
【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026
Medicilon Webinar | IND-enabling Toxicity Studies, CTD Documentation and Translational Cardiac Risk Assessment
RACI Congress 2026

Medicilon Academy

【Case Study】New Approach Methods NAMs
【Case Study】Route, Solid-State, and Impurity Optimization (Small-Molecule API)
【Case Study】IND Completion in 12 Months (Small-Molecule NCE)
Boston Non-Tumor Models Innovation
【White Paper】Navigating the DMPK Gauntlet: A Strategic Analysis of the Interconnected Challenges Shaping the Future of Drug Development
【White Paper】Patient-Derived Xenograft Organoids: Advancements and Applications in Precision Oncology

Digital Materials

A Sensitive LC–MS Bioanalytical Method for Simultaneous Quantification of Structurally Similar Cyclic Tetrapeptides at the Picogram Level (Download)
Quantification of antibody-Conjugated Drug in Cleavable ADCs: A Universal, Automated, and Cost-Effective LC-MS/MS Platform (Download)
Leveraging a Humanized SLE Mouse Model to Evaluate Next-Generation Immune-Cell-Targeted Therapeutics (Download)
Integrated Mass Spectrometric Workflows Enabling Next-Generation Conjugate Therapeutics in Cancer Research (Download)
From Sequence Design to AOC Production Medicilon’ s End-to-End RNAi Development Platform (Download)
Developing PDX-Derived Organoid Models for Efficacy Evaluation of Anticancer Therapies (Download)

Search Medicilon

Preclinical CRO

【BRIDGE】Medicilon XDC Innovation Forum · Seoul 2026

Preclinical CRO

Medicilon’s Formulation CDMO Platform Advances Taiji Group’s Next-Generation RNA Polymerase Inhibitor DSC158A Tablets to Clinical Stage

Preclinical CRO

TPD CN-US Dual Filing Milestone: Medicilon’s One-Stop Platform Helps Gluetacs Secure Dual Approval for GT818, a First-in-Class RSK Degrader

Contact Medicilon

Name(Required)
Address(Required)